Abstract P357: Gender Disparities in Utilization of Statins in Patients With Cancer and Atherosclerotic Cardiovascular Disease: Results From Houston Methodist Learning Health System Outpatient Registry

Abstract

Background: Gender disparities in utilization of statins have been reported across patients with cardiovascular disease, however these patterns remain unknown amongst cancer patients. We sought to evaluate gender differences in statin use amongst cancer patients with atherosclerotic cardiovascular disease (ASCVD) using data from a large US healthcare system. Methods: Houston Methodist Learning Health System Outpatient Registry was utilized to obtain data of adult population between 2016 to 2022. All patients with a cancer and ASCVD diagnosis listed on their problems list using the ICD-10 CM codes were included. Statin use and dose were identified in the database using ATC codes, and this information was recorded based on medication reconciliation reviews with patients at each clinical encounter. Multivariate logistic regression analysis and chi-square test were utilized to compare statin use between the two genders. Results: A total of 16,926 patients with cancer and ASCVD were included (41.6% women). Women with cancer and ASCVD reported lower statin use (63.9% vs 73.7%; p<0.01) and lower high-intensity statin use (27.5% vs 37.2%; p<0.01) compared with men. Women with cancer and ASCVD were also less likely to have LDL-C<70mg/dL (25.8% vs 35.2%; p<0.01) compared with men. Consistent results were observed even after adjusting for demographic and cardiovascular risk factors (any statin OR 0.68 [0.63, 0.72]; high-intensity statin OR 0.66 [0.61, 0.70]). These disparities persisted across age (<65, ≥65 years) and racial/ethnic (NHW, Hispanics, NHB, Asian/Other) strata. Conclusion: Although statins can potentially ameliorate risk of adverse cardiovascular events in patients with cancer, significant gender disparities exist in utilization of statins among US patients with cancer and established ASCVD, with women less likely to have guideline defined goal of LDL<70 mg/dL and receive any and high-intensity statin therapy across age and racial/ethnic subgroups.